Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Pacific Biosciences of California Inc Market Cap
From what 6 stock analysts predict, the share price for Pacific Biosciences of California Inc (PACB) might increase by 64.53% in the next year. This is based on a 12-month average estimation for PACB. Price targets go from $1 to $7. The majority of stock analysts believe PACB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedPACB 2 buy ratings, 4 hold ratings, and 0 sell ratings. This means that analysts expect Pacific Biosciences of California Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PACB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PACB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sung Ji Nam Scotiabank | Sector Outperform | $7 | Maintains | Aug 28, 2024 |
Stephens & Co. | Overweight | Maintains | Aug 13, 2024 | |
| Tejas Savant Morgan Stanley | Equal-Weight | $2 | Maintains | Aug 12, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $3.5 | Reiterates | Aug 8, 2024 |
| Kyle Mikson Canaccord Genuity | Buy | $3 | Maintains | Aug 8, 2024 |
| Tycho Peterson Jefferies | Buy | $4 | Initiates | Jun 3, 2024 |
| Tejas Savant Morgan Stanley | Equal-Weight | $4 | Maintains | May 15, 2024 |
| David Westenberg Piper Sandler | Neutral | $2 | Maintains | May 13, 2024 |
| Luke Sergott Barclays | Equal-Weight | $2 | Maintains | May 10, 2024 |
| Rachel Vatnsdal JP Morgan | Neutral | Downgrade | Apr 22, 2024 | |
| Matthew Sykes Goldman Sachs | Neutral | $2.5 | Maintains | Apr 19, 2024 |
| Matthew Sykes Goldman Sachs | Neutral | $2.5 | Downgrade | Apr 18, 2024 |
| Eve Burstein Bernstein | Outperform | $2.5 | Maintains | Apr 18, 2024 |
| Sung Ji Nam Scotiabank | Sector Outperform | $8 | Maintains | Apr 18, 2024 |
| Daniel Brennan TD Cowen | Buy | $2.5 | Maintains | Apr 17, 2024 |
| Luke Sergott Barclays | Equal-Weight | $3 | Maintains | Apr 10, 2024 |
| Matthew Sykes Goldman Sachs | Buy | $7 | Maintains | Apr 10, 2024 |
Canaccord Genuity | Buy | Maintains | Mar 22, 2024 | |
| John Sourbeer UBS | Buy | $12 | Maintains | Feb 16, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $11 | Initiates | Dec 14, 2023 |
When did it IPO
2010
Staff Count
796
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Christian O. Henry M.B.A.
Market Cap
$468.7M
In 2023, PACB generated $200.5M in revenue, which was a increase of 56.29% from the previous year. This can be seen as a signal that PACB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 28 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Pacific Biosciences (NASDAQ:PACB) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation into Pacific Biosciences for potential securities law violations raises concerns about transparency and could impact stock performance and investor confidence.
Sun, 29 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Pacific Biosciences (NASDAQ:PACB) for potential securities law violations related to misleading statements affecting investors.
Why It Matters - The investigation into Pacific Biosciences for potential securities law violations may indicate legal risks and possible financial repercussions, affecting investor confidence and stock performance.
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Pacific Biosciences (NASDAQ:PACB) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation into Pacific Biosciences for potential securities law violations could lead to legal issues and financial repercussions, impacting investor confidence and stock performance.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating Pacific Biosciences (NASDAQ:PACB) for potential securities law violations, including misleading statements affecting investors.
Why It Matters - The investigation into Pacific Biosciences for potential securities law violations may indicate underlying issues, impacting investor confidence and stock performance.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - PacBio granted a non-qualified stock option for 100,000 shares and RSUs for 50,000 shares to a new employee, effective September 23, 2024, under its 2020 Inducement Plan.
Why It Matters - The granting of stock options and RSUs signals PacBio's commitment to retaining talent, which can enhance innovation and growth, potentially impacting future stock performance positively.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Pacific Biosciences of California (PACB) closed at $1.75, reflecting a 0.57% increase from the previous trading day.
Why It Matters - PACB's slight increase in stock price indicates potential investor confidence or market interest, which can influence trading volume and future price movements.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
